CAR-NK cell therapy platform

Natural killer (NK) cells are emerging as an increasingly important cell type for therapeutic development for multiple diseases. Using induced pluripotent stem cell (iPSC)-derived cell therapies has multiple advantages for developing sophisticated, armored CAR-NK cell therapies.

Edited iPSC-derived CAR-NK cell therapies are a compelling platform for cell therapy development

iPSCs are amenable to higher numbers of genome-editing events than most primary cells, allowing for sophisticated armoring

We have developed robust differentiation and expansion protocols to derive NKs from iPSCs


CAR-NK platformCAR-NK platform

Using induced pluripotent stem cells (iPSCs), we are able to generate and armor genome-edited CAR-NK cells to address the challenges of treating multiple diseases by armoring cells for targeting, trafficking, proliferation, and overcoming the immunosuppressive tumor microenvironment.